17 The effect of postoperative ketorolac on hemoglobin and postoperative pain control after vaginal surgery S. Shah, D. Thompson, H. Goldstein OB/GYN, Christiana Care Health System, Newark, DE OBJECTIVES: Ketorolac is an appealing alternative to narcotics in postoperative pain management. However, there is concern for postoperative bleeding with its use. Postoperative bleeding after vaginal reconstructive surgery is a well-established complication and can present acutely secondary to bleeding from the vaginal cuff, vascular pedicles or with deteriorating vital signs indicative of a retroperitoneal hematoma. With conflicting evidence in the literature on postoperative bleeding with ketorolac use, we sought to evaluate and compare the effect of ketorolac on postoperative bleeding and to assess its impact on postoperative pain control. MATERIALS AND METHODS: This is a retrospective cohort study of women who had vaginal reconstructive surgery at Christiana Care Health System between January 1, 2014 and December 31, 2014. Patients were identified through CPT codes for vaginal reconstructive surgeries that required an inpatient stay. Data on preoperative and postoperative hemoglobin levels as well as total narcotic use was collected for each patient. The total narcotic use was then converted to IV hydromorphone using an opioid equivalence conversion. Data analysis was performed using a chi-square test and unpaired t-test to assess the differences in demographics and clinical characteristics of patients who received ketorolac and those who did not receive ketorolac. Multiple regression and linear regression analyses were performed to assess the effect of ketorolac use on hemoglobin and total narcotic use. RESULTS: One hundred twenty-nine vaginal surgery cases were identified in the study period. Of those cases, 54 (41.9%) patients received ketorolac and 75 (58.1%) patients did not receive ketorolac. There was no statistically significant difference in mean narcotic use between the ketorolac group and the no ketorolac group (3.85 mg vs 3.0 mg, p ¼ 0.194). Total ketorolac use was not associated with an increase in estimated blood loss (p ¼ 0.169). Among patients who received ketorolac, there was no significant difference in pre-operative and post-operative hemoglobin when adjusting for estimated blood loss. One patient had a retroperitoneal hematoma and had not received ketorolac. One patient required a blood transfusion and had not received ketorolac. CONCLUSION: This study found that that there was no difference in change in hemoglobin with the use of ketorolac. The total amount of narcotic use was not decreased in patients who received ketorolac postoperatively for additional pain control.
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Shivani Shah: Nothing to disclose; Dana Thompson: Nothing to disclose; Howard Goldstein: Nothing to disclose. Oral Posters ajog.org guidelines require two T&S from separate venipunctures, which is burdensome to the patient and adds cost. With the increasing frequency of minimally invasive urogynecologic surgery, transfusion rates may be lower than historically reported. Thus, our primary objective was to compare blood transfusion rates between three routes of apical prolapse repairs (vaginal, abdominal, laparoscopic, or robotic) in an effort to identify the current need for T&S. Our secondary objective was to assess the prevalence of a positive antibody screen.
MATERIALS AND METHODS:
We conducted a retrospective cohort study of 536 consecutive patients undergoing apical prolapse surgeries between May 2005 and June 2016 at a single academic institution. Route of surgery was based on the type of apical prolapse repair: uterosacral or sacrospinous ligament fixation (vaginal), open sacral colpopexy (abdominal), or laparoscopic or robotic sacral colpopexy (MIS). The primary outcome was intraoperative or postoperative red blood cell transfusion during the index hospitalization. Patients with bleeding disorders, anticoagulant use, or combined surgery with other services were excluded. We abstracted data from electronic medical records regarding age, race, parity, Charlson comorbidity index (CCI), surgical history, smoking status, body mass index (BMI), prolapse stage, estimated blood loss, concomitant procedures, and intraoperative complications. Existing literature reported similar transfusion rates for vaginal and MIS surgery; thus, we estimated that we needed 139 patients per group to detect a difference between 2% in vaginal or MIS cases versus 10% in abdominal procedures at 80% power and an alpha of 0.05. RESULTS: Among 536 subjects, there were 176 (33.8%) vaginal, 182 (34.0%) abdominal, and 178 (33.2%) MIS. Comparing our three groups, there were no differences in race, parity, CCI, smoking status, BMI, intraoperative complications, or uterine weight. Variables that differed between groups included: age (59.1 AE 12.3 vs 52.5 AE 10.9 vs 59.6 AE 10.2, p ¼ 0.01), stage 3-4 prolapse (54.7% vs 79.7% vs 59.6%, p < 0.001) and concomitant hysterectomy (74.3% vs 20.8% vs 31.3%, p < 0.001) for vaginal, abdominal and MIS routes, respectively. For our primary outcome, 22 (4.1%) patients received a blood transfusion overall. The rate of transfusion was significantly higher in the abdominal group (11.0%) compared to the vaginal (0.6%) and MIS (0.6%) routes, p < 0.001. In a logistic regression model, abdominal sacral colpopexy (OR 15.2, 95% CI ¼ 1.9-130.7) and age by decades (OR ¼ 1.6, 95% CI ¼ 1.0-2.6) remained significantly associated with transfusion when also adjusting for advanced prolapse and hysterectomy. Among the 515 (96.1%) subjects who underwent a preoperative T&S, only 6 (1.1%) had a positive antibody screen. CONCLUSION: Transfusion risk was lower for vaginal and minimally invasive apical prolapse repairs than for abdominal sacral colpopexy. The prevalence of a positive antibody screen in this population was low. These data suggest that transfusion with apical prolapse repairs, particularly vaginal or MIS, is rare and that T&S may be less necessary than historically suggested.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS:
Taylor Brueseke: Nothing to disclose; Maggie Wilkins: Nothing to disclose; Marcella Willis-Gray: Nothing to disclose; Katherine Husk: Nothing to disclose; Elizabeth J. Geller: Nothing to disclose; Jennifer M. Wu: Nothing to disclose. Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH OBJECTIVES: To assess the incidence of blood transfusion following pelvic reconstructive surgery in a large national surgical quality database and to identify transfusion-associated factors. MATERIALS AND METHODS: This retrospective cohort study was performed using the National Surgery Quality Improvement Program (NSQIP) database from the years 2009-2014. All women undergoing surgery for pelvic floor disorders were identified by CPT code. The incidence of blood transfusion was calculated. A multivariate logistic regression analysis was performed to estimate the odds of blood transfusion for various factors while controlling for other covariates. Data were analyzed using Stata 13.0. RESULTS: In the NSQIP database, there were 54,408 women who underwent pelvic reconstructive surgery from 2009-2014. The median age of patients was 57 years (range ¼ 28-89). The majority of patients were overweight or obese, 35.6% (BMI ¼ 25-29.9) and 36.7% (BMI !30), respectively. Most patients were white (91.4%), with 4.6% being African Americans, and the remainder being Asian, American Indian/Alaska Native, or Native Hawaiian/Pacific Islander. Hispanic ethnicity was reported by 9.3% of patients. American Society of Anesthesiologists (ASA) Class 1 and 2 represented a majority of the sample (76.5%). Concomitant hysterectomy was performed in 38.1% of the population. The incidence of blood transfusion in this population was 1.28% (n ¼ 696). In the multivariate analysis, preoperative hematocrit less than 30 (odds ratio [OR] ¼ 18.9), history of coagulopathy (OR ¼ 3.4), concomitant hysterectomy (OR ¼ 1.7), and BMI <18.5 (OR ¼ 1.9) were statistically significantly associated (p < 0.05) with receiving a postoperative blood transfusion. When compared to ASA Class I, patients who were Class 3 (OR ¼ 2.2), or Class 4 (OR ¼ 5.2) had a statistically significantly increased odds of blood transfusion. When compared to white patients, African Americans (OR ¼ 1.8) and Hispanics (OR ¼ 1.9) had a statistically significant increased odds of postoperative blood transfusion. In this cohort, overweight and obese subjects had a decreased odds of transfusion (OR ¼ 0.7). When compared to women ages 30-59, women less than 30 (OR ¼ 2.9) and over 65 (OR ¼ 1.09) had a statistically significant increased odds of transfusion while women ages 60-64 (OR ¼ 0.7) had decreased odds of transfusion. CONCLUSION: Transfusion after pelvic reconstructive surgery is rare. The variables that are associated with transfusion are preoperative hematocrit less than 30, ASA class, bleeding disorders, concomitant hysterectomy, underweight status, and age less than 30 and over 65. Recognition of these factors can help guide preoperative counseling regarding transfusion risk after pelvic reconstructive surgery and individualize preoperative preparation.
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